Mirabegron

Phase 1/2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Erectile Dysfunction

Conditions

Erectile Dysfunction, Overactive Bladder, Urinary Incontinence

Trial Timeline

Aug 1, 2017 → Jan 1, 2020

NCT ID

NCT02916693

About Mirabegron

Mirabegron is a phase 1/2 stage product being developed by Astellas Pharma for Erectile Dysfunction. The current trial status is completed. This product is registered under clinical trial identifier NCT02916693. Target conditions include Erectile Dysfunction, Overactive Bladder, Urinary Incontinence.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05621616	Phase 3	Active	Feb 28, 2024	Sep 30, 2026	Neurogenic Detrusor Overactivity
NCT04562090	Approved	Completed	Jan 6, 2021	Mar 30, 2022	Urge Incontinence
NCT04501640	Approved	Completed	Sep 21, 2020	Oct 27, 2020	Pharmacokinetics of Mirabegron
NCT02981459	Approved	Withdrawn	Dec 8, 2017	Jun 1, 2018	Urinary Frequency/Urgency
NCT02916693	Phase 1/2	Completed	Aug 1, 2017	Jan 1, 2020	Erectile Dysfunction
NCT02751931	Phase 3	Completed	Jun 17, 2016	May 6, 2019	Neurogenic Detrusor Overactivity
NCT02526979	Phase 1	Completed	Dec 17, 2015	Sep 30, 2016	Overactive Bladder
NCT02495389	Approved	Completed	Jan 28, 2015	Jan 29, 2019	Overactive Bladder
NCT02211846	Phase 1	Completed	Sep 21, 2014	Sep 21, 2015	Neurogenic Detrusor Overactivity
NCT01898624	Pre-clinical	Completed	Dec 4, 2012	Jan 10, 2018	Overactive Bladder
NCT02570035	Pre-clinical	Completed	Dec 1, 2012	Mar 1, 2015	Overactive Bladder
NCT00939757	Phase 1	Completed	May 1, 2009	Jul 1, 2009	Healthy
NCT01285596	Phase 1	Completed	Mar 1, 2009	Nov 1, 2009	Healthy Volunteers
NCT01579461	Phase 1	Completed	Nov 1, 2008	Apr 1, 2009	Pharmacokinetics

Competing Products

20 competing products in Erectile Dysfunction

See all competitors

Product	Company	Stage	Hype Score
tadalafil + placebo	Eli Lilly	Phase 3	77
YHD1023 + YHD1023 + YHD1023 + Cialis + Placebo	Yuhan	Phase 2	52
Tacrolimus + Placebo	Astellas Pharma	Approved	85
LY2452473 + Tadalafil + LY900010	Eli Lilly	Phase 1	33
tadalafil + placebo	Eli Lilly	Phase 3	77
tadalafil	Eli Lilly	Phase 3	77
LY2452473 + tadalafil + placebo (tadalafil) + placebo (LY2452473)	Eli Lilly	Phase 2	52
Tadalafil	Eli Lilly	Approved	85
tadalafil + placebo	Eli Lilly	Approved	85
Tadalafil + Sildenafil Citrate	Eli Lilly	Approved	85
Tadalafil + Placebo	Eli Lilly	Phase 3	77
Placebo + Tadalafil	Eli Lilly	Approved	85
Tadalafil + Placebo	Eli Lilly	Approved	85
tadalafil	Eli Lilly	Approved	85
Tadalafil + Sildenafil	Eli Lilly	Approved	85
tadalafil once a day [T(OaD)] + sildenafil citrate as needed [S(PRN)] + tadalafil as needed [T(PRN)]	Eli Lilly	Phase 3	77
Tadalafil + Placebo	Eli Lilly	Approved	85
Dapoxetine	Johnson & Johnson	Phase 3	77
dapoxetine	Johnson & Johnson	Phase 3	77
Placebo + Dapoxetine + PDE5I (phosphodiesterase-5 inhibitor)	Johnson & Johnson	Phase 3	77

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved

micafungin + voriconazoleApproved

mirabegron + solifenacinApproved

Zolpidem (Myslee®) + placeboApproved

TacrolimusApproved